Department of Cardiovascular Surgery of the First Affiliated Hospital & Institute for Cardiovascular Science of Soochow University, Suzhou, 215006, China.
Sci China Life Sci. 2014 Feb;57(2):195-200. doi: 10.1007/s11427-013-4605-y. Epub 2014 Jan 15.
It is still unclear whether the timing of intracoronary stem cell therapy affects the therapeutic response in patients with myocardial infarction. The natural course of healing the infarction and the presence of putative homing signals within the damaged myocardium appear to favor cell engraftment during the transendothelial passage in the early days after reperfusion. However, the adverse inflammatory environment, with its high oxidative stress, might be deleterious if cells are administered too early after reperfusion. Here we highlight several aspects of the timing of intracoronary stem cell therapy. Our results showed that transplantation of bone marrow mesenchymal stem cells at 2-4 weeks after myocardial infarction is more favorable for reduction of the scar area, inhibition of left ventricular remodeling, and recovery of heart function. Coronary injection of autologous bone marrow mesenchymal stem cells at 2-4 weeks after acute myocardial infarction is safe and does not increase the incidence of complications.
目前仍不清楚冠状动脉内干细胞治疗的时机是否会影响心肌梗死后患者的治疗反应。梗死的自然愈合过程和损伤心肌内潜在的归巢信号似乎有利于再灌注后早期的跨内皮细胞迁移过程中的细胞嵌合。然而，如果在再灌注后过早给予细胞，不利的炎症环境及其高氧化应激可能是有害的。在这里，我们强调了冠状动脉内干细胞治疗时机的几个方面。我们的研究结果表明，在心肌梗死后 2-4 周进行骨髓间充质干细胞移植更有利于减少疤痕面积、抑制左心室重构和恢复心功能。急性心肌梗死后 2-4 周经冠状动脉注射自体骨髓间充质干细胞是安全的，不会增加并发症的发生率。
